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Doravirine (DOR) is a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of human 49 
immunodeficiency virus-1 (HIV-1). Its use in combination with rifapentine (RPT), an anti-tuberculosis 50 
antibiotic, may reduce the exposure of DOR compromising viral suppression in those living with HIV-1 co-51 
infected with tuberculosis. We conducted a prospective, phase I, open label, two-period, fixed sequence, 52 
drug interaction study to evaluate the effect of once-weekly RPT and isoniazid (INH) on the 53 
pharmacokinetics of DOR in healthy volunteers. DOR 100 mg was administered alone twice-daily for 4 54 
days in period 1. In period 2, once-weekly RPT+INH was co-administered with multiple doses of DOR 100 55 
mg twice-daily for study days 7, 14, and 21. Plasma was obtained for DOR pharmacokinetics when given 56 
alone and co-administered with RPT+INH. Eleven healthy volunteers enrolled and completed the study. 57 
The geometric mean ratios and 90% confidence intervals for DOR AUC0-12 and C12 in the presence of 58 
RPT+INH compared to DOR alone were 0.71 (0.60-0.85) and 0.69 (0.54-0.89), respectively. Although 59 
exposures were moderately reduced in the presence of RPT+INH, trough DOR values were within the 60 
concentration range associated with virological suppression.  These results demonstrate that a modest 61 
decrease in doravirine exposure would unlikely be clinically relevant in a virally suppressed patient co-62 












Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with 73 
other antiretrovirals (ARV) for the treatment of HIV-1 infection in adults. It is non-inferior to current 74 
standard of care ARV regimens with fewer adverse events.1, 2 The elimination of doravirine is primarily 75 
through metabolism via cytochrome P450 (CYP) 3A mediated oxidation to an M9 metabolite.3 In vitro 76 
studies demonstrate low potential of interference from the parent or metabolite on phase I and II 77 
metabolizing enzymes and drug transporters.3 Therefore, doravirine has a lower potential for drug-drug 78 
interactions compared to other NNRTIs and does not impact the pharmacokinetics of other drugs. 79 
Considering the predominant route of elimination is through CYP3A, co-administration with strong 80 
inhibitors and inducers may alter the pharmacokinetic profile of doravirine.  81 
The Centers for Disease Control and Prevention (CDC) currently recommends several latent 82 
tuberculosis infection (LTBI) treatment options for persons with HIV and includes either once-daily 83 
isoniazid for nine months, rifampin or rifabutin once-daily for four months, or once-weekly rifapentine 84 
and isoniazid for three months.4 The rifamycin class of anti-tuberculosis agents are strong inducers of 85 
CYP enzymes, including CYP3A, with rifabutin being the less potent inducer of the three. Co-86 
administration with multiple-doses of rifampin significantly reduced doravirine trough concentrations by 87 
97% with multiple-dose rifabutin similarly reducing troughs by 68%.5, 6 With the exception of rifabutin, 88 
where twice-daily doses of doravirine are predicted to overcome the interaction6, the use of rifampin 89 
and rifabutin together with once-daily doses of doravirine is contraindicated.    A three month 90 
rifapentine based regimen has comparable efficacy and safety compared to lengthy once-daily anti-91 
tuberculosis regimens.7 The magnitude of drug-drug interaction between doravirine when co-92 
administered with rifapentine and isoniazid has not been defined.   93 
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 The objective of this study was to evaluate the effects of once-weekly rifapentine and isoniazid 94 
on the steady-state pharmacokinetics of twice-daily doravirine, and to assess the safety and tolerability 95 
of these co-administered drugs.    96 
Methods 97 
The study was approved by the Thomas Jefferson University Institutional Review Board and 98 
registered on clinicaltrials.gov (NCT03886701). The study was conducted in accordance to Good Clinical 99 
Practice standards and applicable federal and/or local regulatory requirements. All participants provided 100 
written informed consent prior to beginning the study.  101 
Study population  102 
Healthy HIV and TB negative adult men or non-pregnant women between 18-60 years old with a 103 
body mass index of 19-33 kg/m2 weighing between 45-120 kg at screening were enrolled in the study. 104 
Women of childbearing potential and their partners were required to use acceptable methods of 105 
contraception during the time of the study and until four weeks after the last dose of drug. Women who 106 
were postpartum for less than 12 months were excluded. Other exclusion criteria included any clinically 107 
significant disease, current drug or alcohol abuse, known anaphylactic or systemic reactions to doravirine, 108 
rifapentine, or isoniazid, and those who have received another study drug within four weeks or five half-109 
lives (whichever occurring first).  110 
Study design and treatments 111 
This was a phase I, prospective, open-label, two-period, fixed-sequence, drug-drug interaction 112 
study conducted in healthy volunteers. (Figure 1) Subjects received doravirine 100 mg twice-daily for 113 
four study days during the first period. In the second period, once-weekly weight based rifapentine and 114 
isoniazid and pyridoxine 50 mg was co-administered with doravirine 100 mg twice-daily. The doses of 115 
rifapentine were weight based and included 900 mg (>50 kg) or 750 mg (32.1-49.9 kg) with a 900 mg 116 
maximum dose. Isoniazid was given as a 15 mg/kg dose and rounded up to the nearest 50 or 100 mg 117 
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with a maximum dose of 900 mg. The doses and dosing schedule for rifapentine, isoniazid, and 118 
pyridoxine were selected based on the Centers for Disease Control and Prevention treatment regimens 119 
for LTBI.4 Subjects received a light meal prior to each doravirine dose for study days 1-4. For the morning 120 
of study days 7, 14, and 21, isoniazid and pyridoxine was dosed following an overnight fast with 121 
doravirine and rifapentine dosed after the subject received a meal. For days 8-13 and 15-20, subjects 122 
received a light meal before each dose of doravirine. All subjects received 8 ounces of water with each 123 
dose.  124 
Pharmacokinetic sampling and bioanalysis  125 
Plasma samples for doravirine were collected at pre-dose (0 hour), 0.5, 1, 1.5, 2, 3, 6, 12, 24, 36, 126 
48 and 72 hours post dose on study days 4-7 (period one) and study days 21-24 (period two). A pre-dose 127 
sample was taken for all subjects prior to starting period 1 and doravirine dosing to ensure no previous 128 
doses of doravirine were taken. A doravirine trough concentration was collected on study days 15, 16, 129 
and 20 prior to the administration of the second doravirine dose. Approximately 3 mL of blood was 130 
collected into K2-EDTA vials and inverted 8-10 times before being centrifuged at 3000 rpm for 10 131 
minutes. Plasma was aliquoted into a cryotube and was stored at -20°C before analysis. Plasma 132 
doravirine concentrations were determined using a validated ultra-performance liquid chromatography 133 
tandem mass spectrometry with a lower limit of quantification of 1 ng/mL over a calibration range of 1-134 
1000 ng/mL (developed and validated by Syneos Health Clinique, Quebec, QC, Canada).  135 
Safety and tolerability  136 
Safety and tolerability were assessed throughout the study and included monitoring for adverse events, 137 
physical exams, vital signs, electrocardiograms, and laboratory safety tests (blood chemistry, 138 
hematology, and urinalysis). Laboratory safety assessments were conducted in period 1 (study day 5) 139 
and period 2 (study days 8, 15, and 22).  140 
Pharmacokinetic and statistical analysis  141 
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Plasma doravirine pharmacokinetic parameters were estimated using a non-compartmental 142 
analysis and performed on R version 3.6.1 with the PKNCA and ncappc packages. Doravirine 143 
pharmacokinetic parameters included the area under the concentration-time curve during the dosing 144 
interval (AUC0-12), steady-state trough plasma concentration at the end of the dosing interval (C12), 145 
average steady-state plasma drug concentration during multiple dose administration (Cavg), peak plasma 146 
concentration at steady-state (Cmax), terminal elimination half-life (t1/2), apparent clearance at steady-147 
state (CLss/F), and the accumulation ratio for both periods.     148 
The parameters AUC0-12, C12, Cavg, and Cmax were separately evaluated using a generalized estimating 149 
equations (GEE) model with log-link with the primary predictor of period. Geometric means and 150 
corresponding 95% confidence intervals were calculated for each treatment group. The 90% confidence 151 
intervals were estimated from the GEE model for the geometric mean ratios for (doravirine + rifapentine 152 
+ isoniazid)/doravirine) alone. The statistical analysis was performed on R version 3.6.1 with the geepack 153 
package.8 Sample size was calculated from the reported variability in doravirine trough concentration in 154 
HIV-infected men (1540 nmol/L and 95% CI: 1110-2140 nmol/L).9  Using a significance level of 5% with a 155 
two-sided paired t-test, a sample size of 11 provided greater than 80% power to detect a change of 50% 156 
in doravirine trough concentrations. The magnitude of change was selected on the assumption that a 157 
50% change in trough concentrations would be clinically significant.   158 
 159 
Results 160 
Subject demographics 161 
Eleven subjects (10 male and 1 female) were enrolled and completed the study with a mean (+SD) age of 162 
46.4 (+ 9.9) years old. Subjects were Black or African American (73%) or white (27%). Mean body 163 
weights were 92.9 kg (range 75.5-109.4 kg) which allowed the maximum doses of rifapentine and 164 
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isoniazid (900 mg) for all subjects during the study. The mean (+SD) body mass index was 31.2 (+2.6) 165 
kg/m2. All subjects were included in the PK and safety analysis.   166 
Doravirine plasma concentration time profile  167 
All pharmacokinetic data were included in the analysis and figures. All subjects had undetectable 168 
doravirine concentrations in plasma at pre-dose prior to beginning study day 1. Two subjects had 169 
undetectable doravirine concentrations in plasma at the 72-hour time point in the second period (study 170 
day 24). Mean doravirine plasma concentration profiles alone and in combination with rifapentine and 171 
isoniazid for all sampled points was plotted against time (figure 2). The mean doravirine plasma 172 
concentration during the dosing interval for doravirine alone or in combination with rifapentine and 173 
isoniazid is shown in figure 3. Co-administration with once-weekly rifapentine and isoniazid modestly 174 
reduced the steady-state AUC0-12, C12, Cavg, and Cmax by 29%, 31%, 29%, and 25%, respectively. Figure 4 175 
displays the individual and geometric mean ratios for rifapentine + isoniazid + doravirine/doravirine 176 
alone AUC0-12, C12, Cavg, and Cmax. Rifapentine co-administration reduced doravirine half-life by 58% while 177 
increasing the steady-state total plasma clearance by 41% (table 1).   178 
Safety and Tolerability  179 
 Doravirine in combination with rifapentine and isoniazid was generally well tolerated with no 180 
serious adverse events. Adverse events were mild in intensity with 9 out of 11 subjects (82%) reporting 181 
at least one adverse event. The most common adverse event throughout the study was intravenous 182 
catheter site pain and redness (45.5%) where blood sampling occurred. Nausea and vomiting was the 183 
most common reported adverse event (9%) during period 1 where doravirine was dosed alone. During 184 
the second period where doravirine was co-administered with weekly rifapentine and isoniazid, one 185 
subject (9%) reported dysuria following the second week of rifapentine and isoniazid dosing. The same 186 
subject reported chills, headache, and a fever following the third week of dosing rifapentine and 187 
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isoniazid. These symptoms subsided and were resolved two days after the report adverse event. All 188 
laboratory parameters were within normal limits during the course of the study. 189 
   190 
Discussion 191 
In patients infected with HIV and LTBI, the current therapeutic options include daily rifampin or 192 
rifabutin for 4 months or isoniazid daily for 9 months. Although both INH and rifamycin based regimens 193 
are similarly effective in the treatment of LTBI in patients with HIV, patients are more likely to complete 194 
shorter and convenient regimens. While rifapentine and isoniazid affords a shorter duration and dosing 195 
frequency for treatment than INH monotherapy, drug interaction studies are infrequent to evaluate this 196 
regimen co-administered with HIV antiretroviral therapies.  197 
In this study, twice-daily doses of doravirine 100 mg dosed to steady-state was selected based 198 
on nonparametric superposition predictions from a single dose drug interaction study with rifabutin.6 199 
Furthermore, doravirine was generally well tolerated across multiple doses of up to 750 mg with robust 200 
antiviral activity at 200 mg once-daily in patients with HIV-1 with a terminal half-life of approximately 15 201 
hours.9, 10 Therefore, a twice-daily dosing regimen for 4 days was selected in the first period for several 202 
reasons: 1) given the safety profile of doravirine reported previously, a 100 mg twice-daily dose of 203 
doravirine is expected to not be a safety concern, 2) it is expected that the 100 mg twice-daily doses of 204 
doravirine should obtain the same level of virological efficacy as seen with patients dosed 200 mg once-205 
daily, and 3) steady-state exposure is expected within 3 days of dosing allowing steady-state doravirine 206 
concentrations to be sampled by the fourth study day in the first period.     207 
Doravirine is contraindicated when co-administered with drugs that are strong CYP3A inducers. 208 
The current study evaluated the pharmacokinetics of steady-state doravirine in the presence of 209 
rifapentine and isoniazid. Once-weekly doses of rifapentine and isoniazid moderately reduced doravirine 210 
steady AUC0-12 and C12 following twice-daily doses of 100 mg doravirine in healthy volunteers. This 211 
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reduction in exposure is reflected by the increase in doravirine steady-state clearance (8.4 L/hour versus 212 
5.9 L/hour) and a shortened half-life (15.2 hours versus 6.4 hours) in the presence of rifapentine and 213 
isoniazid. Rifapentine is a potent inducer of CYP450 metabolizing enzyme specifically impacting CYP3A4, 214 
CYP2C8, and CYP2C9 isoenzymes.11 The potency of induction is 45% greater than rifabutin, with rifampin 215 
being the most potent of the anti-tuberculosis rifamycins.12 Therefore, this reduction in exposure with 216 
subsequent increase in doravirine clearance was expected as seen in previous drug interaction studies, 217 
where rifampin and rifabutin co-administration significantly reduced doravirine trough values following 218 
once-daily dosing.5, 6 This study reinforces the time-dependent change in the metabolic induction 219 
capacity of once-weekly rifapentine. As seen in figure 5, mean doravirine C12 concentrations reached a 220 
nadir approximately 2 days following rifapentine dosing (study day 14).  221 
In phase II studies doravirine doses of 25 mg and 200 mg have comparable virological efficacy in 222 
patients with HIV-1 with geometric mean C24 values at 107 ng/mL (77-149 ng/mL).9 While there is no 223 
established therapeutic range that correlates with clinically sustained virological suppression and 224 
efficacy, an NNRTI class-specific steady-state concentration 6-fold above the in vitro 50% inhibitory 225 
concentration (IC50) for wild type HIV would result in approximately 99% maximal viral reduction.15 In 226 
the case of doravirine, the in vitro IC50 is 5.1 ng/mL which results in a pharmacokinetic target of 31.5 227 
ng/mL.16 Although doravirine mean steady-state trough values at the second week of rifapentine dosing 228 
were below the observed C24 in pivotal trials (figure 5), concentrations still remained 7.6-fold above the 229 
values associated with maximal viral load reduction. Moreover, the nadir trough values seen at the 230 
second week of rifapentine and isoniazid dosing were >50% of the values following a 25 mg dose in the 231 
patient population where the antiviral activity was comparable to the higher dose levels. Based on the 232 
strong correlation of doravirine trough values in the exposure-response relationship, trough 233 
concentrations seen in this study are within the ranges associated with a >80% proportion of individuals 234 
achieving HIV-1 RNA copies of <50 copies/mL.17  235 
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It should be noted that a true nadir cannot be defined given the absence of trough collections 236 
on study days 17-19. Using the elimination rate and distribution volume of doravirine in the presence of 237 
rifapentine observed in this study, trough values were predicted for study days 16-19 (figure 6). The 238 
mean plasma trough concentrations at 12 and 24 hours was predicted to be 376.4 ng/mL suggesting 239 
that concentrations of doravirine can be sustained above the IC50 during a once weekly course of 240 
rifapentine.  Although we observed a persistent reduction of up to 82% in doravirine C12 six days 241 
following the last dose of rifapentine, the time-dependent metabolic induction is nonetheless similar to 242 
reports in literature which observed up to 2-4 days of maximal induction following rifapentine 243 
administration.13, 14     244 
There were minimal adverse events observed in this study. Compared to previous reports using 245 
this regimen in drug interaction studies with other HIV-1 antiretrovirals,14  co-administration of 246 
doravirine with once-weekly rifapentine and isoniazid at maximum doses was well tolerated. The most 247 
common adverse event reported by 45.5% of subjects was intravenous catheter site pain and redness 248 
which was unrelated to the study drugs. Only one female subject reported flu-like symptoms which 249 
included fever, chills, and headache after the second dose of rifapentine, isoniazid, and doravirine. This 250 
was anticipated, as a high incidence of flu-like symptoms have been reported following high dose 251 
rifapetine and isoniazid, particularly in older aged white women.18 Furthermore, safety lab value trends 252 
were within the normal ranges throughout the entirety of the study.  253 
Several limitations should be noted. The study did not analyze the primary metabolite, M9, 254 
which is a direct result of CYP-mediated oxidation. In the presence of an inducer such as rifapentine and 255 
twice-daily dosing of doravirine, the exposure of M9 is expected to increase. The impact of the M9 256 
metabolite on safety is unclear, as M9 is present as only 13% of parent dose, does not accumulate with 257 
repeated dosing, and does not  have activity against HIV reverse transcriptase.19 The study also enrolled 258 
mostly male participants (10 male vs. 1 female). Although there was a gender imbalance in this study,  259 
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gender does not impact the pharmacokinetics of doravirine.17 Lastly, doravirine trough concentrations 260 
were not collected for study days 17-19 during period two of the study. As such a true nadir cannot be 261 
confirmed with certainty during that period where doravirine was co-administered with rifapentine and 262 
isoniazid.  263 
In summary, once-weekly oral rifapentine and isoniazid moderately reduced the AUC0-12 and C12 264 
of twice-daily 100 mg doravirine by 29% and 31%, respectively. This reduction, however, was within the 265 
trough values associated with virological efficacy seen in pivotal clinical studies. As a result, doravirine 266 
100 mg administered twice-daily may be considered to mitigate the drug interaction effect of 267 
rifapentine where the modest reduction in doravirine exposure is unlikely to be clinically relevant in a 268 
virally suppressed patient.  269 
 270 
Study Highlights 271 
What is the current knowledge of the topic?  272 
Co-infection with latent tuberculosis in persons living with Human Immunodeficiency Virus-1 (HIV-1) is 273 
common. Rifapentine is an anti-tuberculosis antibiotic available as once-weekly treatment for latent 274 
tuberculosis and is a potent inducer of cytochrome (CYP) 3A metabolic enzyme. There are limited 275 
studies that evaluate rifapentine in the presence with antiretrovirals, including doravirine, a novel non-276 
nucleoside reverse transcriptase inhibitor metabolized by CYP3A. 277 
What question did this study address?  278 
This study evaluated the pharmacokinetics of twice-daily doravirine when co-administered with once-279 
weekly rifapentine and isoniazid.   280 
What does this study add to our knowledge?  281 
Following rifapentine-mediated CYP3A induction, doravirine steady-state trough concentrations 282 
declined in a time-dependent manner. Steady-state clearance of doravirine increased with a >50% 283 
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reduction in plasma half-life following co-administration with rifapentine and isoniazid. Despite this 284 
reduction, doravirine exposure is in a range that is likely to maintain viral suppression.  285 
How might this change clinical pharmacology or translational science?  286 
Doravirine 100 mg given twice-daily can mitigate the interactive effects of once-weekly rifapentine. Co-287 
administration was generally well tolerated with a modest decrease in doravirine exposure unlikely to 288 
be clinically relevant. This dosing regimen may offer an alternative to virally suppressed patients on 289 
antiretroviral therapy co-infected with latent tuberculosis and considering a rifapentine based regimen.   290 
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Figure and Table Legends 352 
Table 1. Steady-state doravirine pharmacokinetic parametersa and summary statistics following twice-353 
daily doses of doravirine 100 mg alone or twice-daily doravirine 100 mg co-administered with once-354 
weekly rifapentine and isoniazid.  355 
 Doravirine + 
rifapentine 
Doravirine Doravirine + rifapentine / 
Doravirine 
Parameter  Geometric mean (95% CI) Geometric mean ratio 
(90% CI) 
AUC0-12 (hr x ug/mL) 12.3 (10.4-14.3) 17.3 (14.9-20.0) 0.71 (0.60-0.85) 
C12 (ug/mL) 0.9 (0.7-1.0) 1.2 (1.0-1.4) 0.69 (0.54-0.89) 
 
Cavg (ug/mL)b 1.0 (0.8-1.2) 1.4 (1.2-1.7) 0.71 (0.60-0.85) 
Cmax (ug/mL) 1.3 (1.1-1.5) 1.7 (1.5-2.0) 0.75 (0.63-0.88) 
t1/2 (hr)c 6.4 (17.0) 15.2 (19.4)  
CL/F (L/hr)c 8.4 (26.1) 5.9 (24.0)  
Accumulation ratio 1.2-1.6 1.8-3.2  
a. Parameters with exposures are expressed as ug/mL. 356 
b. The average steady-state plasma concentration during multiple-dose administration was computed as 357 
AUC0-12/dosing interval.  358 




Figure 1. Study schematic. B6 = vitamin B6 (pyridoxine), BID = Twice-daily, DOR = doravirine, INH = 363 
























Figure 2. Mean (+ SD) doravirine plasma concentration-time profiles following twice-daily doses of 386 
doravirine 100 mg alone or together with once-weekly rifapentine and isoniazid. The inset represents 387 
























Figure 3. Mean (+ SD) doravirine plasma concentration-time profiles during the 12 hour dosing interval 410 
following twice-daily doses of doravrine 100 mg alone or together with once-weekly rifapentine and 411 
isoniazid. Sampling at time 0 and 12 hours were taken prior to the second dose of doravirine. The inset 412 





















Figure 4. Individual ratios (Doravirine/doravirine + rifapentine), geometric mean ratios, and 432 
corresponding 90% confidence intervals for doravirine exposure parameters. AUC0-12 = Area under the 433 
concentration time during the 12 hour dosing interval, C12 = plasma concentration at the end of the 434 
dosing interval prior to the second dose, Cavg = average steady-state plasma concentration during the 435 

























Figure 5. Trend of doravirine C12 concentrations throughout the study study days across the two study 459 
periods. The values represent the geometric mean C12 concentration reported for that study day. Day 5 460 
was used as a reference to calculate the percent change in C12  concentrations for subsequent days. The 461 
green down arrows indicate rifapentine, isoniaizd, and pyridoxine co-administered with the morning 462 
dose of doravirine 100 mg. The horizontal red line indicates the steady-state pharmacokinetic target 6-463 
fold above the IC50 associated with 99% viral reduction. The horizoantal blue line represents the steady-464 
state C24 (% coefficient of variance) values observed in pivotal studies following once-daily doses of 465 
doravirine 100 mg. B6 = pyridoxine, C12 = observed trough concentration prior to the second dose for a 466 
twice-daily regimen, C24 = observed trough concentration prior to the second dose for a once-daily 467 

















Figure 6. Predicted mean doravirine plasma concentrations at study days 16-19. The gray shaded regions 483 
represent the standard error of the mean. Predictions were based on doravirine pharmacokinetic 484 
parameters estimated following co-administration of rifapentine on day 21.  485 
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 487 
